|Brand name(s), other common name(s)||EMPLICITI™|
|Drug type||Immunostimulatory antibody|
|How the drug is given||Injection|
Indications and Usage
Elotuzumab is FDA approved for the treatment of multiple myeloma as combination therapy with lenalidomide and dexamethasone in patients who have received one to three prior therapies.
Side effects needing medical attention
Infusion reactions (such as fever, trouble breathing, chills, dizziness, rash, light-headedness); infections; risk of new cancers (malignancies); liver problems; fatigue; numbness, weakness, tingling, or burning pain in your arms or legs; diarrhea; sore throat or runny nose; fever; upper respiratory tract infection; constipation; decreased appetite; cough; pneumonia.